微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 33.52% | 2.98% | -1.12% | 107/158 | -2.04% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 33.9% | 3.67% | 3.12% | 108/158 | 14.94% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 32.87% | 2.64% | -1.02% | 107/158 | 32.08% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 33.21% | 2.5% | 2.03% | 114/158 | 51.81% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 32.55% | 2.17% | -0.46% | 113/158 | 22.66% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 32.7% | 3.06% | 2.09% | 114/158 | 33.21% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 32.03% | -2.54% | -1.15% | 113/158 | 51.68% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 32.4% | 1.56% | 1.7% | 114/158 | 51.58% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 31.86% | 0.27% | 0.41% | 114/158 | 32.59% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 31.73% | -3.03% | -3.45% | 118/158 | 38.52% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 32.86% | -2.73% | 3.01% | 113/158 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 31.9% | 3.97% | 0.41% | 118/158 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 31.77% | 1.61% | -2.9% | 110/158 | 6.03% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 32.72% | 0.56% | -3.14% | 113/158 | 21.28% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 33.78% | -2.78% | 10.09% | 103/158 | 54.44% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 30.69% | -7.16% | -1.87% | 124/158 | 55.28% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 31.27% | -8.98% | -3.9% | 109/158 | 46.93% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 32.54% | -9.34% | -6.36% | 117/158 | 47.39% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 34.75% | -14.08% | 5.14% | 97/158 | 54.24% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 33.05% | 3.14% | -3.8% | 123/158 | -147.15% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 34.36% | 6.23% | -4.28% | 102/158 | 56.61% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 35.89% | 7.63% | -11.25% | 106/158 | 54.34% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 40.44% | 16.05% | 26.2% | 81/158 | 55.43% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 32.05% | 10.55% | -0.91% | 115/158 | -1232.32% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 32.34% | 9.57% | -3.02% | 91/158 | 55.43% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 33.35% | 9.68% | -4.31% | 95/158 | 55.42% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 34.85% | 10.09% | 20.22% | 85/158 | 51.19% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 28.99% | 10.97% | -1.78% | 118/158 | -209.94% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 29.51% | 12.81% | -2.92% | 89/158 | 54.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 30.4% | 14.17% | -3.95% | 91/158 | 53.57% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 31.65% | 12.43% | 21.18% | 83/158 | 54.1% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 26.12% | 7.61% | -0.16% | 111/158 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 26.16% | 3.7% | -1.75% | 86/158 | 49.3% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 26.63% | 0.81% | -5.42% | 87/158 | 48.06% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 28.15% | -0.39% | 15.99% | 66/158 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 24.27% | 1.24% | -3.79% | 100/158 | 48.52% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 25.23% | 3.62% | -4.48% | 69/158 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 26.41% | 4.9% | -6.55% | 75/158 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 28.27% | 4.1% | 17.89% | 60/158 | 43.86% | 贝达药业 | 97.01% | 行业排名> |